الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 128 |  |  |
| | | from | 128 | | |
Abstract
Rheumatic heart disease kills around 300000 people in endemic countries.
Rheumatic mitral disease surgery has traditionally involved mechanical valve replacement. Short-term results are reliable with low mortality and uncommon postoperative stenosis or regurgitation. Due to thrombosis and bleeding risks, its mid-term results are poor.
Fu and colleagues from China shared their experience and a meta-analysis comparing mitral valve repair and replacement results. The repair group had lower early mortality, valve-related events, and reoperation rates. In 1171 patients, Kim and colleagues from Korea showed no significant difference in long-term mortality or reoperation rate between repair and replacement groups, while repair patients had fewer valve-related problems.
Chen and colleagues from Taiwan performed propensity matching on 5086 patients who had surgery for rheumatic mitral valve disease with a mean follow-up of 6 years and found no difference in mortality or reoperation rates between repair and replacement. Luo and colleagues have proposed a grading system for rheumatic mitral repair. In their 921 mid-term outcomes, the replacement group had more heart failure and valve-related problems.
Degenerative valve disease is rare in high-income nations, thus valve repair research and surgery have focused on it. Rheumatic valve disease is neglected. Rheumatic heart disease received the least funding proportionate to its importance in a worldwide burden of disease research. Thus, we must improve rheumatic heart disease research and establish regional centers of excellence to serve our people.
The main results of the study showed that: